Cardiac Biomarkers Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)

Cardiac Biomarkers Market Trends and Growth Drivers

Usage of AI and ML for Cardiac Biomarker Identification Is Major Trend

• The requirement for biomarkers that can better provide information concerning predictive, prognostic, and diagnostic implications is leading to advancements in this sensitive analytical technique.
• The integration of artificial intelligence (AI) and machine learning (ML) with diagnostic platforms improves the identification of biomarkers, allowing for personalized therapeutic approaches in cardiology.
• AI-driven algorithms can analyze complex data on biomarkers, helping clinicians understand the patterns related to early cardiac events that traditional biomarkers might not detect.
• The systems enhance predictive modeling for cardiovascular risk, thereby assisting practitioners diagnose and prognose reliably. For instance, AI-enabled tools better read and interpret troponin levels, CRP, and BNP, thus speeding up the detection of ACS or heart failure.
• The incorporation of biomarkers with wearable devices and remote monitoring systems enables faster tracking and monitoring of patient health and minimizes hospital readmissions.
• AI-enhanced biomarkers also help in building individualized therapeutic strategies in cardiology with specifically designed interventions based on the unique cardiac profile of each individual. This confirms the best therapeutic outcome, driving the transition toward personalized medicine and improving long-term heart health management.
• Furthermore, the integration of PoC kits with AI-based analytics in clinical settings delivers quicker, more-reliable, and better patient outcomes.

Increasing Prevalence of CVDs Boosts Demand for Cardiac Biomarkers

• The market for cardiac biomarkers is growing due to the rising prevalence of CVDs. According to the WHO, approximately 17.9 million deaths globally are caused by CVDs each year, which is 32% of all global fatalities. Moreover, the number of deaths from CVDs and strokes is forecast to rise to 23.6 million by 2030. 
• The increasing prevalence of CVDs is due to the sedentary lifestyles, unhealthy eating habits, rising incidence of obesity, and soaring levels of stress.
• This has raised the demand for rapid and specific techniques for the early diagnosis of cardiac disorders and to prevent them from entering the severe stages.
• Cardiac biomarkers have emerged as vital tools in detecting heart damage, monitoring disease progression, and tracking the effect of treatment.
• Various market players are aiming to offer test kits for the detection of biomarkers that enable a better understanding of the pathogenesis of CVDs.
• Major biomarkers include B-type natriuretic peptide (BNP), C-reactive protein, N-terminal prohormone BNP, lipoprotein-associated phospholipase A2, and cystatin C.
• The adoption of biomarkers in the diagnosis of ACS and creation of personalized treatment strategies is an essential factor driving the market.
• Furthermore, the collaborations among healthcare providers and diagnostics solution companies for bringing new biomarker technologies increase their availability and accessibility.

Limited Specificity of Cardiac Biomarker Hinders Market Growth

The problem with cardiac biomarkers lies in their limited specificity, meaning they can indicate heart damage, but can also detect non-cardiac conditions, including kidney disease, infections, or extreme physical stress. This overlap can lead to false positives or misdiagnoses, creating confusion among clinicians in ascertaining that the elevated levels of the are because of a cardiovascular event. This requires additional diagnostic testing, such as imaging studies or repeat biomarker testing.

Such delays compromise treatment decisions and the outcomes for the patient. This limitation hampers the growth of the cardiac biomarkers market due to the less confidence in its standalone reliability. This makes healthcare providers reluctant to use these tests extensively, particularly in emergencies, due to their risk of misdiagnoses.

Cardiac Biomarkers Market Analysis

Type Analysis

Troponins account for the major revenue share of, over 30%, in 2024 in the market, and this category is expected to grow with a robust CAGR during the forecast period. This is due to the extraordinary specificity and capacity of their protein complex to help accurately recognize cardiac problems, such as ACS. Additionally, the high prevalence of myocardial infarction will drive the market, as troponin is now the most common tool to detect this condition.

B-type natriuretic peptides (BNPs) are the fastest-growing category in the market, due to their significant role in the early diagnosis and management of congestive heart failure (CHF). With the increasing prevalence of CHF all over the world, BNP and NT-proBNP are becoming increasingly used in monitoring disease progression. As per estimates, 6.2 million people in the U.S. have CHF.

Moreover, in April 2024, Roche Diagnostics India launched a POC NT-proBNP test exclusively on the Cobas h 232 system. It allows for the screening of diabetic patients at risk of cardiovascular diseases, including heart failure. This test seeks to enable early detections and timely interventions for high-risk type 2 diabetes patients.

The types evaluated here:

• Troponins (Largest Category)
• Myocardial Muscle Creatine Kinase
• Myoglobin
• BNPs (Fastest-Growing Category)
• IMA
• ALT/AST
• Others

Application Analysis

Myocardial infarction is the second highest revenue contributor, with 35% share, in 2024, and this category is further expected to dominate the market during the forecast period. This is due to its rising incidence globally because of the changing lifestyles, unhealthy food, excessive smoking, hypertension, diabetes, hyperlipidemia, family history of obesity, and coronary artery disease.

Because a quick and accurate diagnosis is vital for avoiding fatalities due to acute myocardial infarctions, PoC testing kits, alongside lab-based assays, have become utmost important in emergency departments. Cardiac biomarkers, such as troponins and CK-MB, are the most commonly used for the diagnosis, monitoring, and risk stratification of myocardial infarctions and other acute coronary syndromes.

The fastest-growing category in the cardiac biomarker market is congestive heart failure. The cause most commonly linked to CHF is coronary artery disease, with others including high cholesterol levels and/or triglyceride levels in the blood. In terms of biomarkers, B-type natriuretic peptide and N-terminal prohormone BNP have become significant in diagnosing CHF, monitoring its progression, and estimating prognostic outcomes.

These biomarkers are used to evaluate the severity of heart failure, make treatment-related decisions, and monitor a patient's response to therapy. Furthermore, the surge in the demand for biomarker tests for the early detection of heart failure is the key factor set to boost the cardiac biomarkers market growth in the coming years.

The applications analyzed here are:

• Myocardial Infarction (Largest Category)
• Congestive Heart Failure (Fastest-Growing Category)
• Atherosclerosis
• Others

Testing Location Analysis

Laboratory testing accounts for the larger revenue share, and this category is expected to maintain its position during 2025–2030. This is due to the increase in healthcare spending and the number of reforms for healthcare infrastructure improvement, rise in the disposable income, and the government and private sectors’ initiatives aimed at preventing heart diseases.

The point-of-care testing category will grow with the higher CAGR, of 15.0%, during the forecast period because doctors are increasingly adopting this approach to monitor patients with chest pain in critical care centers.

The testing locations analyzed here are:

• Laboratory Testing (Largest Category)
• Point-of-Care Testing (Fastest-Growing Category)

Regional Analysis

The North American cardiac biomarkers market accounted for the largest revenue share, of over 40%, in 2024. The dominance of the region can be attributed to the increasing usage of biomarkers for precision medicine, different growth strategies implemented by market players, and the increasing adoption of biomarkers for the detection of cardiac diseases.

The U.S. contributes the majority of the revenue to the regional market as it is the base for several market players and accounts for a high R&D expenditure in the healthcare sector.

APAC will be the fastest-growing market for such biomarkers, with a CAGR of around 14.0%, during the forecast period. This can be attributed to the growing healthcare infrastructure, various government schemes for the healthcare sector, high investment by market giants, high prevalence of cardiac diseases, and rising aging population.

China holds the largest regional cardiac biomarkers market share, and it will witness significant growth in the coming years. The high morbidity and mortality due to CVDs, the government’s Healthy China 2030 plan, and the availability of advanced imaging, coronary stenting, and other technologies will boost the market growth in the country.

India is the most significant contributor to the market, following China, in the region. This is due to the rising cases of heart failure in adults because of the evolving lifestyles, improvements in specialized treatment approaches, and government schemes supporting the healthcare sector.

In addition, Europe holds a significant revenue share in the global market due to the presence of prominent research institutions and market players. Furthermore, the industry growth can be ascribed to the rising number of collaborations between regional universities and biomarker providers, governments and market players’ R&D initiatives related to biomarkers, and the strong efforts being taken to create awareness about the benefits of biomarkers.

The geographical breakdown of the market is as follows:

• North America (Largest Regional Market)
  • U.S. (Larger Country Market)
  • Canada (Faster-Growing Country Market)
• Europe
  • Germany (Largest Country Market)
  • U.K. (Fastest-Growing Country Market
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia-Pacific (APAC) (Fastest-Growing Regional Market)
  • China (Largest Country Market)
  • India (Fastest-Growing Country Market)
  • South Korea
  • Japan
  • Australia
  • Rest of APAC
• Latin America (LATAM)
  • Brazil (Largest Country Market)
  • Mexico (Fastest-Growing Country Market)
  • Rest of LATAM
• Middle East and Africa (MEA)
  • Saudi Arabia (Largest Country Market)
  • U.A.E. (Fastest-Growing Country Market)
  • South Africa
  • Rest of MEA

Cardiac Biomarkers Market Share

The cardiac biomarker market is consolidated in nature due to the presence of a few key players that hold large market shares. This results from the stringent clinical protocols and regulatory approvals, as biomarker tests need to meet the requisite standards of accuracy, reliability, and safety. Huge investments are required for research and development, thus giving an advantage to the big and established corporations that have access to the latest technologies and resources. Furthermore, strategic partnerships and collaborations with healthcare professionals and clinical settings solidify the position of the top firms.

Cardiac Biomarkers Market News

In June 2024, Siemens Healthineers improved its Atellica Solution cardiac testing capabilities with the introduction of the NT-proBNPII assay, which helps in the enhanced detection of heart failure. Both N-terminal pro-BNP and B-type natriuretic peptides are vital markers released because of an increase in ventricular filling pressure. The NT-proBNPII assay delivers results within 10 minutes, thereby allowing for timely patient care, and it can be performed on the Atellica IM or CI analyzer.

In October 2023, Shenzhen Mindray Bio-Medical Electronics Co. Ltd. expanded its cardiac biomarker portfolio with the addition of high-sensitivity troponin I and NT-proBNP assays. These biomarkers are critical for facilitating the early screening, risk stratification, and rapid diagnosis of acute coronary syndromes and heart failure. The hs-cTnI assay boasts a detection rate of 93%, with minimal imprecision of 5%.